A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2018

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms BREEZE AD-1
  • Sponsors Eli Lilly; Eli Lilly Japan
  • Most Recent Events

    • 26 Mar 2018 Planned End Date changed from 1 Jan 2021 to 1 Jan 2019.
    • 26 Mar 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2018.
    • 09 Mar 2018 Planned End Date changed from 15 Feb 2019 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top